LUCENTIS
Manufacturer Details
NOVARTIS
Compositions:
Ranibizumab 10mg per ml injection,
|
Strength
|
Rate
|
Packing Style
|
|
10mg/ml inj
|
75000.00
|
0.3ml injection
|
List of Related Indications:
List Of Drugs:
- Ranibizunab -@- Ophthalmic agents - Selective Vascular Endothelial Growth Factor Antagonist
Indication Type Description:
Drug Interaction:
Drug interaction-
Vertoporin photodynamic therapy ( PDT ) -
ranibizumab intravitreal injectiion has been used adjunctively with verteporfin PDT
Indication:
Macular degeration
Adverse Reaction:
Severe adverse reactions related to the injection have occured in less than 0.1% intravitreal
injections, including endophthalmitis, iatrogenic traumatic cataracts, and rhegmatogenous
retinal detachments
Contra-Indications:
Ocular or periocular infections known hypersenstivity to ranibizab or any of its
components
Special Precautions /Warnings-
Endophthalmitis and retinal detachments-
Intravitreal injections, including those with rhambizumab have been associated with
endophthalimitis and retinal detachments. Use proper asceptic techniques when
administering ranizumab. Monitor patients following injection to permit early treatment
of any injection.
Increased intraocular pressure-
Increase in intraocular pressure have been noted within 60 minutes of intraocular
injection with ranizumab. Monitor and manage intraocular pressure
Pregnancy - give ranizumab to a pregnant woman only if clearly required
Lactation- excercise caution when ranizumab is administered to breast feeding woman
Children- safety and efficacy of ranizumab in children have not established
Dosages/ Overdosage Etc:
Indication-
Macular degeration
Dosage-
Adminster 0.5mg ( 0.05ml ) by intravitreal injection once a month.
Although less effective, treatment may be reduced to 1 injection every 3 months after
the first 4 injections , if monthly injection is not feasible
Storage - refrigerate at 2 to 8C ( 36 to 46F ). Do not freeze. Do not use beyond the date
stamped on the label. store original carton until time for use
Patient Information:
1. Advice patient that they are at risk of developing endophthalmtis in the days folowing
ranizumab administration
2. If the eye becomes red , sensitive to light, painful or develops a change in vision advice
the patient to seek immediate care from an ophthalmologist.
Pregnancy and lactation:
Pregnancy -
Give ranizumab to a pregnant woman only if clearly required
Lactation-
Excercise caution when ranizumab is administered to breast feeding woman
Children-
Safety and efficacy of ranizumab in children have not established
